Special Reports

Welcome to FiercePharma's look back at our most popular stories and features of 2008. While a number of topics are represented in our top 10 stories, layoffs seem to be a recurring theme. A host of

With 2008 behind us, we'd like to take a look back at the stories and special reports our readers found most interesting over the past year. Unlike the 2007 list, which was dominated by Pfizer news,

Synta rings in New Year with a new deal The folks at Synta Pharmaceuticals know how to end a year with a bang. While most people were preparing for the Christmas and New Year's holiday bash, Synta

MAP Pharma plots a course toward commercialization As the CEO of a public company, there are things Tim Nelson can't talk about, such as just about everything that MAP Pharmaceuticals hasn't

A fledgling biotech launches a new development platform For a newly-sprouted biotech company, Ascent Therapeutics has some deep scientific roots. The technology dates back to the late ‘90s,

Catalyst Biosciences maps out its (near) future Biotech companies have always touted each new round of investment capital as a tangible validation of their development work. And with the capital

Welcome to the November installment of "FDA News in Review," where each month we look at the agency's latest decision, approvals, warnings and recalls. With a new president on his way to the office,

Arete Therapeutics adopts a thrifty approach to drug development With its lead program safely through Phase I testing and a lineup of investors satisfied with the discovery path Arete Therapeutics

Radius Health maps out its next two years About eight months ago, Radius Health CEO C. Richard Lyttle, PhD, took a hard look at the company's budget as well as the increasingly shaky state of affairs

Welcome to our second annual report on the top five layoffs of the year. Companies like Pfizer, AstraZeneca and Bayer posted the biggest numbers in 2007. In 2008, patent expirations, drug safety